Document:

INTEROFFICE MEMO

TO:               Fred Marroni

FROM:             John Manzetti

Subject:          2002 Compensation Plan

Date:             December 17, 2001

CC:               Jill Welch

Dear Fred,

This letter is to confirm and to outline the components of your compensation
plan for 2002 as Vice President of Engineering and Development for NOMOS
Corporation.

Effective January 1, 2002 your annual base salary will be increased to $175,000,
a $10,000, or 6.1% increase over your current annual base salary of $165,000.
Your new anniversary date will not be January 1. Your compensation plan will
also include an annual bonus opportunity of $100,000, up from $75,000 in 2001.

As we discussed, for 2002, your incentive plan opportunity will be as follows:

         Personal and Department Objectives:
                  $40,000 will be earned on your achievement of personal and
                  department objectives we will agree upon, which will provide
                  Sales and Marketing with needed features and functionality in
                  a timely, and cost effective manner.

         Company Financial Performance:
                  $30,000 will be earned if the Company meets its base 2002
                  Financial Plan, yet to finalized by the Compensation Committee
                  of the Board of Directors.

                  $30,000 will be earned if the Company exceeds its base 2001
                  Financial Plan targets, yet to finalized by the Compensation
                  Committee of the Board of Directors.

Your total Compensation opportunity for 2002 is:

         Base Salary at 1/1/02 (annualized)            $   175,000
         Personal & Department Objectives                   40,000
         Company Financial performance                      60,000
                                                        ----------
         Total at 100% achievement                     $   275,000

Any bonus amount earned will be paid within 45 days after the financial closing
of fiscal year 2002 and no later than February 28, 2003

Any discrepancies will be discussed individually, and with your input, and after
consideration of all factors, I will decide on the final resolution.

Fred, I really enjoy working with you to solve problems and strategize on new
business opportunities. Let's do it again and again.

Best regards,

John

<PAGE>

                            [NOMOS Corporation Logo]

Mr. Fred Marroni
9892 Mocassin Trail
Wexford, PA 15090

                                                  July 2, 2001

Dear Fred,

This letter is to confirm and outline the components of you compensation plan
for 2001 as Vice President of Engineering, and an officer of NOMOS Corporation,
reporting to me.

Your annual base salary will be $165,000 and will be paid semi-monthly effective
on you start date, which I hope is on or before August 1, 2001. Your
compensation plan will also include an annual bonus opportunity of $75,000. This
incentive opportunity will be prorated on your start date, and if that date is
August 1, 2001, you will be eligible to earn 5/12ths of you annualized bonus
opportunity as follows:

         Personal and Department Objectives:
                  $10,417 (5/12ths of $25,000) will be earned on your
                  achievement of personal and department objectives we will
                  agree upon during the first 30 days of your employment.

         Company Financial Performance:
                  $10,417 (5/12ths of $25,000) will be earned if the Company
                  meets its base 2001 Financial Plan targets of $24M in revenue
                  and $4.6M in operating income.

                  $10,417 (5/12ths of $25,000) will be earned if the Company
                  exceeds its base 2001 Financial Plan targets, and achieves
                  revenue of $28.8M and operating income of $5.5M.

In addition, 100,000 incentive stock options will be granted to you on your
start date. These options vest equally over a three-year period as per the terms
of the 2001 NOMOS Corporation Stock Option Plan. This Plan is designed to reward
you handsomely for increased Company valuation.

Any performance bonus amount earned will be paid within 60 days after the
financial closing of fiscal year 2001 and no later than February 28, 2002.

You will also receive a $15,000 one-time signing bonus, which will be paid at
the end of your first 30 days of employment. Should you terminate your
employment with NOMOS voluntarily within 12 months of your start date, this
bonus is to be repaid to NOMOS Corporation immediately upon your termination and
may be withheld from or netted against any final pay due to you at that time.

<PAGE>

Your total annualized compensation package is then $240,000, not including the
one-time bonus opportunity.

You will also receive employee benefits, which include:
                  A fully paid comprehensive medical/detntal/vision plan
                  A short- and long-term disability plan
                  A life insurance plan
                  401(k) plan including company match
                  Participation in company profit sharing program
                  Vacation to accrue at 3 weeks per year
                  Tuition Reimbursement per current Company policy

The Company reserves the right to alter or exchange employer provided benefits
as necessary.

As a valued member of the NOMOS senior management team, you will also receive an
enhanced severance agreement which will pay your base salary for twelve (12)
months in the event you are terminated for any reason other than for cause. This
severance will be paid over normal semimonthly payroll periods. This agreement
will also be honored in the event of a change of control of NOMOS Corporation
where another company acquires control of NOMOS and your job is eliminated or
your duties are diminished. If your job is not eliminated under a change of
control, then either the severance package will be transferred to the acquiring
company or it will be honored and paid by NOMOS Corporation.

If you agree with and accept the terms of this letter, please sign below and
return this letter to NOMOS Human Resources office. You will be required to sign
the NOMOS Confidentiality and Proprietary Rights Agreement, a copy of which is
enclosed for your perusal. Please sign and return it with this letter.

Best regards,

/s/   John W. Manzetti

John W. Manzetti
President and Chief Operating Officer

                                             Accepted by:

                                             /s/   Fred Marroni        7-11-01
                                             ---------------------------------
                                             Fred Marroni                 Date<PAGE>

                                                                EXHIBIT 10.19(c)

CONFIDENTIAL TREATMENT REQUESTED: CONFIDENTIAL PORTIONS OF THIS DOCUMENT HAVE
BEEN REDACTED AND HAVE BEEN FILED SEPARATELY WITH THE COMMISSION.

                                 AMENDMENT TWO
                                       TO
                               LIMITED EXCLUSIVE
                             PATENT, COPYRIGHT AND
                          TRADEMARK LICENSE AGREEMENT

                                      FOR

                     PEREGRINE(TM) DOSE CALCULATION SYSTEM

                        FOR RADIATION TREATMENT PLANNING

                                    BETWEEN

                  THE REGENTS OF THE UNIVERSITY OF CALIFORNIA

                                      AND

                               NOMOS CORPORATION

                            LLNL CASE NO. TL-1613-99

                     LAWRENCE LIVERMORE NATIONAL LABORATORY
                            UNIVERSITY OF CALIFORNIA
                    P.O. BOX 808, L-795, LIVERMORE, CA 94551
                 INDUSTRIAL PARTNERSHIPS AND COMMERCIALIZATION

                                   JUNE 2002
<PAGE>

CONFIDENTIAL TREATMENT

                                 AMENDMENT TWO

NOMOS Corporation                                   Radiation Treatment Planning
                                                                   Amendment Two
--------------------------------------------------------------------------------

                                 AMENDMENT TWO
                                   June 2002

                                       to

                License Agreement - LLNL Case Number TL-1613-99
                   For PEREGRINE(TM) DOSE CALCULATION SYSTEM
                        For Radiation Treatment Planning
                         between NOMOS Corporation and
                  The Regents of the University of California
                            effective July 20, 1999

This Amendment Two to the License Agreement by and between The Regents of the
University of California ("THE REGENTS") and NOMOS Corporation ("LICENSEE")
will be effective as of the date of execution of this Amendment by both
Parties. This Amendment and the associated License Agreement are subject to
overriding obligations to the Federal Government pursuant to the provisions of
THE REGENTS' Contract No. W-7405-ENG-48 with the United States Department of
Energy ("DOE") for the operation of the Lawrence Livermore National Laboratory
("LLNL").

This Amendment Two will modify the field of use, some performance obligations,
and royalty fees as reflected in the amended Exhibits B (RIGHTS GRANTED AND
PERFORMANCE OBLIGATIONS) and C (FEES AND ROYALTIES). All other terms and
conditions remain the same.

Therefore, in consideration of the mutual covenants and obligations recited
herein, THE REGENTS and LICENSEE hereby amend the License Agreement as follows:

1.  EXHIBIT B (RIGHTS GRANTED AND PERFORMANCE OBLIGATIONS) AND EXHIBIT C (FEES
    AND ROYALTIES) are replaced in their entirety as follows:

--------------------------------------------------------------------------------

                                       1
<PAGE>

CONFIDENTIAL TREATMENT

                                 AMENDMENT TWO

NOMOS Corporation                                   Radiation Treatment Planning
                                                                   Amendment Two
--------------------------------------------------------------------------------

             EXHIBIT B - RIGHTS GRANTED AND PERFORMANCE OBLIGATIONS

                                     NOTICE
                                     ------

      LICENSEE CONSIDERS INFORMATION IN THIS EXHIBIT B TO BE PROPRIETARY.

B.1   RIGHTS GRANTED

      B.1.1  Rights to Licensed Patents

             Subject to the limitations set forth in this Agreement, THE REGENTS
             hereby grants to LICENSEE an exclusive, nontransferable,
             royalty-bearing license to: 1) make, have made, use, sell, offer
             for sale, and import Licensed Products in the Field of Use, and b)
             practice Licensed Methods in the Field of Use.

      B.1.2  Rights to Licensed Copyrights

             Subject to the terms and conditions of this Agreement, THE REGENTS
             grants to LICENSEE an exclusive, nontransferable, royalty-bearing
             license to duplicate, display, perform, make Derivative Works,
             distribute and have distributed, and sell Licensed Products covered
             by Licensed Copyrights in the Field of Use.

      B.1.3  Rights to Licensed Trademarks

             Subject to the terms and conditions of this Agreement, THE REGENTS
             hereby grants LICENSEE an exclusive license to use Licensed
             Trademarks, in corresponding Territories, as specified in Exhibit E
             (LICENSED TRADEMARKS), on Licensed Products or for Licensed Methods
             in the Field of Use.

--------------------------------------------------------------------------------

                                       2

<PAGE>

CONFIDENTIAL TREATMENT

                                 AMENDMENT TWO
NOMOS Corporation                                   Radiation Treatment Planning
                                                                   Amendment Two
--------------------------------------------------------------------------------

          B.1.4     "Field of Use" means planning human and animal cancer
                    therapies based on tumor radiation with photons or electrons
                    that are generated either by a radiation source external to
                    the patient (teletherapy) or an encapsulated radiation
                    source internal to the patient (brachytherapy).

B.2       SUBLICENSING RIGHTS

          THE REGENTS also grants to LICENSEE the right to issue royalty-bearing
          sublicenses to third parties in the Field of Use, having rights no
          greater than those granted to LICENSEE, provided that LICENSEE has
          exclusive rights in such Licensed Patents, Licensed Copyrights, and
          Licensed Trademarks in the Field of Use at the time of sublicensing.
          LICENSEE may issue sublicenses to Licensed Trademarks only in
          conjunction with LICENSEE's sublicensing of Licensed Patents and
          Licensed Copyrights.

          A Use Sublicense is considered to be a Licensed Product and not a
          sublicense as contemplated in this B.2.

B.3       RIGHTS EXCLUDED

          Rights that are not specifically granted in this Exhibit B or
          elsewhere in this Agreement are specifically excluded from the
          license. In particular, no license, express or implied, is granted to
          LICENSEE to Licensed Trademarks outside the corresponding Territory as
          specified in Exhibit E (LICENSED TRADEMARKS).

B.4       FUTURE RIGHTS

          Licensable WFO Subject Inventions and Licensable WFO Computer Software
          will be added to Exhibit A by amendment.

--------------------------------------------------------------------------------
                                       3
<PAGE>

CONFIDENTIAL TREATMENT

                                 AMENDMENT TWO
NOMOS Corporation                                   Radiation Treatment Planning
                                                                   Amendment Two
--------------------------------------------------------------------------------

B.5      PERFORMANCE OBLIGATIONS

         B.5.1 LICENSEE will proceed diligently to develop, file relevant
               regulatory applications for and attempt to obtain relevant
               regulatory commercialization approvals with respect to the
               manufacturing, marketing, and sale of Licensed Products for all
               uses in the Field of Use.  LICENSEE will file with the U.S. Food
               and Drug Administration at least one 510k Application or PMA
               (Pre-Market Approval) for clearance of Licensed Products for at
               least teletherapy uses within one (1) year of the Effective Date.

               Notwithstanding any other term of this Agreement, for the
               purposes of (a) invoking/complying with the Hatch-Waxman Act (35
               U.S.C. Section 156) and any corresponding rules and regulations
               of the U.S. Patent & Trademark Office regarding patent term
               extension, and (b) seeking regulatory approval of LICENSEE's
               Licensed Products and Licensed Methods, LICENSEE shall act as THE
               REGENTS' agent. To the extend deemed necessary by LICENSEE, in
               good faith, the Parties will cooperate to secure regulatory
               approval of LICENSEE's Licensed Products and Licensed Methods.

         B.5.2 LICENSEE will release for distribution and offer Sales of
               Licensed Products by the later date of either October 1, 2000, or
               within sixty (60) days after the date of FDA clearance for
               teletherapy uses of Licensed Products.

         B.5.3 LICENSEE will have gross revenues from Sales of Licensed Products
               or use of Licensed Methods of at least [***] per calendar year,
               as measured at the close of LICENSEE'S business on December 31 of
               the relevant calendar year, commencing with the later of

---------------
***Confidential material redacted and filed separately with the Commission.

--------------------------------------------------------------------------------

                                       4
<PAGE>

CONFIDENTIAL TREATMENT

                                 AMENDMENT TWO
                                                    Radiation Treatment Planning
NOMOS Corporation                                                  Amendment Two
--------------------------------------------------------------------------------

              calendar year 2004, or the first full calendar year after a
              Licensed Product has been released for distribution and offered
              for sale in accordance with paragraph B.5.2.

     B.5.4    LICENSEE will release for distribution and offer first OEM sale of
              Licensed Products that interface with radiation treatment planning
              systems that are manufactured and sold, or otherwise distributed
              to third parties, by entities other than LICENSEE by the later
              date of either October 1, 2001, or one year after initial release
              for distribution and offer of Sales of Licensed Products as
              defined in B.5.2. To the extent that some commercial entities may
              prefer to sublicense Licensed Patents and Licensed Copyrights
              rather than to purchase Licensed Products on an OEM basis,
              LICENSEE's sublicenses may satisfy this OEM performance
              obligation.

     B.5.5    LICENSEE will release for distribution and offer first sale of
              Licensed Products in the Field of Use for brachytherapy by the
              later date of either October 1, 2004, or within sixty (60) days
              after the date of FDA clearance for brachytherapy uses of Licensed
              Products.

     B.5.6    LICENSEE will release for distribution and offer first sale of
              Licensed Products in the Field of Use for inverse treatment
              planning by the later date of either October 1, 2004, or within
              sixty (60) days after the date of FDA clearance for inverse
              treatment planning uses of Licensed Products.

     B.5.7    LICENSEE will release for distribution and offer first sale of
              Licensed Products in the Field of Use for electron radiotherapy by
              the later date of either October 1, 2004, or within sixty (60)
              days after the date of FDA clearance for electron radiotherapy
              uses of Licensed Products.

--------------------------------------------------------------------------------

                                       5
<PAGE>

CONFIDENTIAL TREATMENT

                                 AMENDMENT TWO
                                                    Radiation Treatment Planning
NOMOS Corporation                                                  Amendment Two
--------------------------------------------------------------------------------

     B.5.8    The sales and other performance requirements specified above may,
              by mutual written consent of LICENSEE and THE REGENTS, be amended
              and/or extended at the written request of LICENSEE to THE REGENTS,
              based upon legitimate business or technical reasons specified in
              reasonable detail in such written request. THE REGENTS will not
              unreasonably withhold its consent to requests made in accordance
              with this paragraph.

     B.5.9    The first progress report will be due on February 28, 2000.

--------------------------------------------------------------------------------

                                       6
<PAGE>

CONFIDENTIAL TREATMENT

                                 AMENDMENT TWO

NOMOS Corporation                                   Radiation Treatment Planning
                                                                   Amendment Two
--------------------------------------------------------------------------------
                         EXHIBIT C - FEES AND ROYALTIES

                                     NOTICE
                                     ------

       LICENSEE CONSIDERS INFORMATION IN THIS EXHIBIT C TO BE PROPRIETARY.

C.1    LICENSE ISSUE FEE

       C.1.1  As partial consideration for this Agreement, LICENSEE will pay to
              THE REGENTS a nonrefundable issue fee of Three Hundred Thousand
              Dollars ($300,000) (License Issue Fee) as follows:

              C.1.1.1 Fifty Thousand Dollars ($50,000.00) to be paid when
              LICENSEE executes the Agreement.

              C.1.1.2 Fifty Thousand Dollars ($50,000.00) to be paid no later
              than October 1, 1999.

              C.1.1.3 Fifty Thousand Dollars ($50,000.00) to be paid no later
              than November 1, 1999.

              C.1.1.4 Fifty Thousand Dollars ($50,000.00) to be paid no later
              than December 1, 1999.

              C.1.1.5 Fifty Thousand Dollars ($50,000.00) to be paid no later
              than January 1, 2000.

              C.1.1.6 Fifty Thousand Dollars ($50,000.00) to be paid no later
              than February 1, 2000.

       C.1.2  THE REGENTS will execute the Agreement after receipt of LICENSEE's
              executed copies of the Agreement and payment of the first
              installment of the License Issue Fee specified in C.1.1.1 above.

--------------------------------------------------------------------------------

                                       7
<PAGE>

CONFIDENTIAL TREATMENT

                                 AMENDMENT TWO
NOMOS Corporation                                   Radiation Treatment Planning
                                                                   Amendment Two
--------------------------------------------------------------------------------

         C.1.3      The License Issue Fee will not be credited against any other
                    royalty or fee due from LICENSEE to THE REGENTS.

         C.1.4      In the event that LICENSEE grants sublicenses, LICENSEE will
                    collect an issue fee equal to or greater than the License
                    Issue Fee. LICENSEE will pay to THE REGENTS fifty percent
                    (50%) of any issue fee from sublicensing.

C.2.     EARNED ROYALTIES

         In addition to the License Issue Fee, LICENSEE will pay THE REGENTS an
         earned royalty equal to eight percent (8%) of Net Sales by LICENSEE and
         any sublicensees. The earned royalty on sales of any Licensed Product
         that is sold as part of a larger product system, shall be based on the
         average Net Sales of that Licensed Product sold separately on a non-OEM
         basis over the relevant royalty reporting period. For the purposes of
         calculating earned royalties, the minimum value of any License Product
         shall be Fifty Thousand Dollars ($50,000.00) for the first two (2) full
         years after the date of initial release for distribution and offer of
         Sales of Licensed Products as specified in B.5.2. The minimum value
         shall be Thirty-Five Thousand Dollars ($35,000.00) for the next two (2)
         full years, and Twenty-Five Thousand Dollars ($25,000.00) thereafter.

         Payments of earned royalties will be in accordance with the
         requirements of Article 4.2 (SUBLICENSING RIGHTS AND OBLIGATIONS),
         Article 5 (FEES, ROYALTIES AND PAYMENTS) and Article 7 (PROGRESS AND
         ROYALTY REPORTS) of this Agreement.

--------------------------------------------------------------------------------
                                       8

<PAGE>

CONFIDENTIAL TREATMENT

                                 AMENDMENT TWO

NOMOS Corporation                                   Radiation Treatment Planning
                                                            Amendment Two
--------------------------------------------------------------------------------

C.3  MINIMUM ANNUAL ROYALTIES

     LICENSEE will pay to THE REGENTS a minimum annual royalty according to the
requirements of Article 5 (FEES, ROYALTIES AND PAYMENTS) and the schedule
below. Earned royalties paid to THE REGENTS for Net Sales during a calendar
year will be accrued and credited against the minimum annual royalty paid for
that same calendar year.

--------------------------------------------------------------------------------
CALENDAR YEAR                    MINIMUM ANNUAL             DUE DATE IN CALENDAR
                                 ROYALTY                            YEAR
--------------------------------------------------------------------------------
    2000                         $35,000.00                      February 28
--------------------------------------------------------------------------------
    2001                         $135,000.00                     February 28
--------------------------------------------------------------------------------
    2002                         [***] of cumulative             February 28
                                 annual revenue* sales
                                 up to [***]

                                 [***] of cumulative
                                 annual revenue sales
                                 greater than [***]
                                 but less than
                                 [***]

                                 [***] of cumulative
                                 annual revenue sales
                                 greater than
                                 [***]
--------------------------------------------------------------------------------
    2003                         Same as 2002                    February 28
--------------------------------------------------------------------------------
    2004                         [***]                           February 28
--------------------------------------------------------------------------------
2005 and thereafter for the      $400,000.00                     February 28
  life of this Agreement
--------------------------------------------------------------------------------

* As used herein, the term "cumulative annual revenue" means any revenue
generated from sales of the Licensed Products or use of the Licensed Methods,
accumulated or realized during the period January 1 to December 31 of a given
year, in this instance, the years 2002, and 2003.

---------------
***Confidential material redacted and filed separately with the Commission.

--------------------------------------------------------------------------------
                                       9

<PAGE>

CONFIDENTIAL TREATMENT

                                AMENDMENT TWO

NOMOS Corporation                                   Radiation Treatment Planning
                                                                   Amendment Two
--------------------------------------------------------------------------------

THE REGENTS and LICENSEE execute this Amendment, in duplicate originals, by
their respective officers who are duly authorized on the day and year that is
written.

NOMOS CORPORATION                            THE REGENTS OF THE
                                             UNIVERSITY OF CALIFORNIA

                                             LAWRENCE LIVERMORE
                                             NATIONAL LABORATORY

By:  /s/ Fred L. Marroni                     By: /s/ Karena McKinley
   ---------------------------------            -------------------------------
           (Signature)                                    (Signature)

Name:       Fred L. Marroni                  Name: Karena McKinley
     -------------------------------              -----------------------------

Title: VP - Engineering & Development        Title: Director, IPAC
      ------------------------------                ---------------------------

Date signed:  June 3            , 2002       Date signed:  June 4        , 2002
            --------------------                         ----------------

--------------------------------------------------------------------------------

                                       10

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00040-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00040-of-00352.parquet"}]]